Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282979780> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4282979780 endingPage "31S" @default.
- W4282979780 startingPage "31S" @default.
- W4282979780 abstract "INTRODUCTION: Uterine fibroids (UFs) are a frequent cause of long-term impairment in health-related quality of life (HRQL), including self-image, interpersonal relationships, and sexual function. Linzagolix is an oral GnRH antagonist being developed for treatment of fibroid-related symptoms at doses that result in full or partial estradiol suppression, both with and without add-back therapy (ABT). METHODS: PRIMROSE 1 and 2 are randomized, double-blind, placebo-controlled Phase 3 trials investigating the efficacy and safety of linzagolix 100 mg and 200 mg once daily, +/- ABT in the treatment of UFs for 52 weeks. Health-related qualify of life was assessed using the 3-month recall version of the Uterine Fibroid Symptom Health-Related Quality of Life (UFS QOL) questionnaire (score range: 0-100, a higher score indicating a better HRQL). RESULTS: After 24 weeks, in the pooled population (n=1012), the HRQL total score estimated mean (95% CI) change from baseline was 21.8 (25.6; 18.1), 28.2 (31.8; 24.5), 32.1 (35.6; 28.5), 31.5 (35.2; 27.8) and 12.7 (16.2; 9.1) in the 100 mg, 100 mg+ABT, 200 mg, 200 mg+ABT and placebo groups, respectively. All differences from placebo were significant ( P <.001). The positive changes in HRQL were maintained at 52 weeks. At week 64, 12 weeks after the end of treatment, the improvements decreased in all treatment groups but did not return to baseline, ranging from a mean (SD) of 12.83 (SD 23.64) to 19.45 (SD 23.83) in the linzagolix arms. CONCLUSION: Linzagolix treatment had substantial beneficial effects on HRQL in women with UFs. The benefits persisted, with improvements not fully returning to baseline 12 weeks after treatment termination." @default.
- W4282979780 created "2022-06-17" @default.
- W4282979780 creator A5003343672 @default.
- W4282979780 creator A5050428416 @default.
- W4282979780 creator A5052083049 @default.
- W4282979780 creator A5058749241 @default.
- W4282979780 creator A5067088712 @default.
- W4282979780 creator A5073212927 @default.
- W4282979780 date "2022-05-01" @default.
- W4282979780 modified "2023-10-18" @default.
- W4282979780 title "Quality of Life Improvements in Women with Uterine Fibroids: Results of Two Phase 3 Trials with Linzagolix [A107]" @default.
- W4282979780 doi "https://doi.org/10.1097/01.aog.0000826748.26150.66" @default.
- W4282979780 hasPublicationYear "2022" @default.
- W4282979780 type Work @default.
- W4282979780 citedByCount "0" @default.
- W4282979780 crossrefType "journal-article" @default.
- W4282979780 hasAuthorship W4282979780A5003343672 @default.
- W4282979780 hasAuthorship W4282979780A5050428416 @default.
- W4282979780 hasAuthorship W4282979780A5052083049 @default.
- W4282979780 hasAuthorship W4282979780A5058749241 @default.
- W4282979780 hasAuthorship W4282979780A5067088712 @default.
- W4282979780 hasAuthorship W4282979780A5073212927 @default.
- W4282979780 hasConcept C126322002 @default.
- W4282979780 hasConcept C126894567 @default.
- W4282979780 hasConcept C142724271 @default.
- W4282979780 hasConcept C159110408 @default.
- W4282979780 hasConcept C168563851 @default.
- W4282979780 hasConcept C204787440 @default.
- W4282979780 hasConcept C27081682 @default.
- W4282979780 hasConcept C2775871022 @default.
- W4282979780 hasConcept C2779951463 @default.
- W4282979780 hasConcept C2780566971 @default.
- W4282979780 hasConcept C2908647359 @default.
- W4282979780 hasConcept C29456083 @default.
- W4282979780 hasConcept C71924100 @default.
- W4282979780 hasConcept C99454951 @default.
- W4282979780 hasConceptScore W4282979780C126322002 @default.
- W4282979780 hasConceptScore W4282979780C126894567 @default.
- W4282979780 hasConceptScore W4282979780C142724271 @default.
- W4282979780 hasConceptScore W4282979780C159110408 @default.
- W4282979780 hasConceptScore W4282979780C168563851 @default.
- W4282979780 hasConceptScore W4282979780C204787440 @default.
- W4282979780 hasConceptScore W4282979780C27081682 @default.
- W4282979780 hasConceptScore W4282979780C2775871022 @default.
- W4282979780 hasConceptScore W4282979780C2779951463 @default.
- W4282979780 hasConceptScore W4282979780C2780566971 @default.
- W4282979780 hasConceptScore W4282979780C2908647359 @default.
- W4282979780 hasConceptScore W4282979780C29456083 @default.
- W4282979780 hasConceptScore W4282979780C71924100 @default.
- W4282979780 hasConceptScore W4282979780C99454951 @default.
- W4282979780 hasIssue "1" @default.
- W4282979780 hasLocation W42829797801 @default.
- W4282979780 hasOpenAccess W4282979780 @default.
- W4282979780 hasPrimaryLocation W42829797801 @default.
- W4282979780 hasRelatedWork W1848581113 @default.
- W4282979780 hasRelatedWork W1999344589 @default.
- W4282979780 hasRelatedWork W2072058977 @default.
- W4282979780 hasRelatedWork W2100007591 @default.
- W4282979780 hasRelatedWork W2169250392 @default.
- W4282979780 hasRelatedWork W4206739081 @default.
- W4282979780 hasRelatedWork W4256514411 @default.
- W4282979780 hasRelatedWork W4282979780 @default.
- W4282979780 hasRelatedWork W4308890665 @default.
- W4282979780 hasRelatedWork W4379653961 @default.
- W4282979780 hasVolume "139" @default.
- W4282979780 isParatext "false" @default.
- W4282979780 isRetracted "false" @default.
- W4282979780 workType "article" @default.